TNF and sarcoidosis: In fact, data from the International Registry [33] reported that 18 (44%) out of 41 patients with sarcoidosis included in the registry were receiving corticosteroids and there were no significant differences in hospitalization rates compared with those who were not, while another study showed that African American patients with chronic sarcoidosis treated with disease-modifying anti-rheumatic drugs (DMARDs) or anti-tumor necrosis factor (TNF) therapy did not have an increased risk of respiratory or life-threatening complications of COVID-19 in comparison with the general population [26].